Global comparative trials of Avastin and Lucentis continue to teach lessons

KOLOA, Hawaii – The list of clinical trials comparing Avastin and Lucentis is getting longer, adding weight to the suggestion that there is no significant difference between the drugs with regard to systemic serious adverse events, a presenter said here. Worlwide, results of six trials have been published: CATT, IVAN, MANTA, GEFAL, BRAMD and LUCAS. “Through 2 years, there was no difference between drugs in rates of death, myocardial infarction or stroke events,” CATT study chair and Chairmanof the Cole Eye Institute, Daniel F. Martin, MD, said at Retina 2014. (Read more...)

Full Story →